The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week our news highlights focus on the drug discovery in the European Union, including… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week our news highlights focus on the drug discovery in the European Union, including… Read More
Cancer Research Horizons, the innovation arm of Cancer Research UK, announced the winners of its third Innovation and Entrepreneurship Awards during an awards ceremony at Merchant Taylors’ Hall, London. Dr Alessia Errico, Associate Director of Search and Evaluation at Cancer Research Horizons, said: “These remarkable innovators demonstrate the determination and… Read More
Biotech company Pila Pharma has raised 20 million Swedish kronor ($2.08 million) in an almost fully covered capital raise, which includes a stock option for future use. Pila Pharma was founded by Danish researcher Dorte Gram, a former researcher at Novo Nordisk and was the first researcher to screen… Read More
DDW’s Megan Thomas went to Cambridge, UK, to learn more about what’s happening in this life science epicentre. She spoke with a number of local companies and attended events, the first of which she writes about here: A conversation with Nicola Thompson, CEO of TRIMTECH Therapeutics. E3 ligases to expand… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In significant news this week, the FDA in the US has removed red tape that… Read More
argenx has announced it will advance ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS). The decision follows the analysis of topline data from the Phase Ib study, in which ARGX-119 demonstrated a favourable safety and tolerability profile. “The… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In significant news this week, the FDA in the US has removed red tape that… Read More
The first patient has been dosed in a global multicentre clinical trial to evaluate ISM3412, a potentially best-in-class, MAT2A inhibitor with novel structure, in patients with locally advanced and metastatic solid tumours. The Phase I study consists of two parts: dose escalation and dose selection optimisation, where participants will receive… Read More
Researchers from Japan have shown that benzaldehyde, a compound responsible for the aroma of almonds, halts the growth and spread of therapy-resistant pancreatic cancer. By preventing various signalling proteins and histone modifiers like Ser28-phosphorylated histone H3 (H3S28ph) from binding to 14-3-3ζ protein, the study has shown that benzaldehyde overcomes therapy… Read More
Optibrium has partnered with Tallinn University of Technology (TalTech) to co-supervise an EU-funded PhD position as part of the INNOCHEMBIO programme1. This research project will focus on developing more accurate metabolism models that will reduce the reliance on costly laboratory experiments while improving speed, efficiency and sustainability in drug discovery. Read More
This is the latest episode of the free DDW narrated podcast, titled “UK Spotlight: Innovation and discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Where is the drug discovery expertise happening in the UK?”, “From the top: Dr… Read More
This is the latest episode of the free DDW narrated podcast, titled “UK Spotlight: Innovation and discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Where is the drug discovery expertise happening in the UK?”, “… Read More
On 30 June 2025, The Milner Therapeutics Institute hosted its annual symposium, a hybrid event hosted at West Road Concert Hall in Cambridge, UK, to bring together leading minds from academia and industry to showcase cutting-edge research and its translation into novel therapeutics. The day featured a line-up of speakers,… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we announce the DDW ‘Creating cures’ programme at SLAS2026, the week’s news highlights emphasise… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we announce the DDW ‘Creating cures’ programme at SLAS2026, the week’s news highlights emphasise… Read More
